A safety evaluation of empagliflozin for the treatment of type 2 diabetes

Ian J Neeland, Usman Salahuddin, Darren K McGuire

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: Empagliflozin is a sodium glucose co-transporter 2 inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) by enhancing urinary glucose excretion. Empagliflozin is effective at lowering glycosylated hemoglobin and was recently proven superior to placebo for reduction of cardiovascular disease (CVD) risk. As with any new drug, there are safety considerations that inform its potential use in patients with T2DM.Areas Covered: Here, we evaluate the safety of empagliflozin and provide an expert opinion as to its current and future role in the treatment of patients with T2DM. A search of the English language literature was performed using PubMed search terms: "empagliflozin", "sodium glucose cotransporter 2 inhibitors", and "drug safety". Articles and bibliographies relevant to the subject were reviewed and additional references known to the authors were included.Expert Opinion: The evidence for empagliflozin is robust with regard to glycemic efficacy and safety. Low risk of hypoglycemia, absence of weight gain, and demonstrated cardiovascular risk reduction support its consideration as a first line medication in addition to metformin for patients with T2DM and CVD. Ongoing trials will continue to address the safety and efficacy of empagliflozin and expand our clinical knowledge of this medication.

Original languageEnglish (US)
Pages (from-to)393-402
Number of pages10
JournalExpert Opinion on Drug Safety
Volume15
Issue number3
DOIs
StatePublished - Mar 3 2016

Fingerprint

Type 2 Diabetes Mellitus
Safety
Expert Testimony
Sodium-Glucose Transporter 2
Cardiovascular Diseases
Therapeutics
Sodium-Glucose Transport Proteins
Symporters
Metformin
Glycosylated Hemoglobin A
Bibliography
Risk Reduction Behavior
Hypoglycemia
PubMed
Pharmaceutical Preparations
Weight Gain
empagliflozin
Language
Placebos
Glucose

Keywords

  • drug safety
  • empagliflozin
  • sodium glucose co-transporter 2 inhibitor
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

A safety evaluation of empagliflozin for the treatment of type 2 diabetes. / Neeland, Ian J; Salahuddin, Usman; McGuire, Darren K.

In: Expert Opinion on Drug Safety, Vol. 15, No. 3, 03.03.2016, p. 393-402.

Research output: Contribution to journalArticle

@article{55773b7b8727421bbbba16892dc57662,
title = "A safety evaluation of empagliflozin for the treatment of type 2 diabetes",
abstract = "Introduction: Empagliflozin is a sodium glucose co-transporter 2 inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) by enhancing urinary glucose excretion. Empagliflozin is effective at lowering glycosylated hemoglobin and was recently proven superior to placebo for reduction of cardiovascular disease (CVD) risk. As with any new drug, there are safety considerations that inform its potential use in patients with T2DM.Areas Covered: Here, we evaluate the safety of empagliflozin and provide an expert opinion as to its current and future role in the treatment of patients with T2DM. A search of the English language literature was performed using PubMed search terms: {"}empagliflozin{"}, {"}sodium glucose cotransporter 2 inhibitors{"}, and {"}drug safety{"}. Articles and bibliographies relevant to the subject were reviewed and additional references known to the authors were included.Expert Opinion: The evidence for empagliflozin is robust with regard to glycemic efficacy and safety. Low risk of hypoglycemia, absence of weight gain, and demonstrated cardiovascular risk reduction support its consideration as a first line medication in addition to metformin for patients with T2DM and CVD. Ongoing trials will continue to address the safety and efficacy of empagliflozin and expand our clinical knowledge of this medication.",
keywords = "drug safety, empagliflozin, sodium glucose co-transporter 2 inhibitor, Type 2 diabetes mellitus",
author = "Neeland, {Ian J} and Usman Salahuddin and McGuire, {Darren K}",
year = "2016",
month = "3",
day = "3",
doi = "10.1517/14740338.2016.1135900",
language = "English (US)",
volume = "15",
pages = "393--402",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - A safety evaluation of empagliflozin for the treatment of type 2 diabetes

AU - Neeland, Ian J

AU - Salahuddin, Usman

AU - McGuire, Darren K

PY - 2016/3/3

Y1 - 2016/3/3

N2 - Introduction: Empagliflozin is a sodium glucose co-transporter 2 inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) by enhancing urinary glucose excretion. Empagliflozin is effective at lowering glycosylated hemoglobin and was recently proven superior to placebo for reduction of cardiovascular disease (CVD) risk. As with any new drug, there are safety considerations that inform its potential use in patients with T2DM.Areas Covered: Here, we evaluate the safety of empagliflozin and provide an expert opinion as to its current and future role in the treatment of patients with T2DM. A search of the English language literature was performed using PubMed search terms: "empagliflozin", "sodium glucose cotransporter 2 inhibitors", and "drug safety". Articles and bibliographies relevant to the subject were reviewed and additional references known to the authors were included.Expert Opinion: The evidence for empagliflozin is robust with regard to glycemic efficacy and safety. Low risk of hypoglycemia, absence of weight gain, and demonstrated cardiovascular risk reduction support its consideration as a first line medication in addition to metformin for patients with T2DM and CVD. Ongoing trials will continue to address the safety and efficacy of empagliflozin and expand our clinical knowledge of this medication.

AB - Introduction: Empagliflozin is a sodium glucose co-transporter 2 inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) by enhancing urinary glucose excretion. Empagliflozin is effective at lowering glycosylated hemoglobin and was recently proven superior to placebo for reduction of cardiovascular disease (CVD) risk. As with any new drug, there are safety considerations that inform its potential use in patients with T2DM.Areas Covered: Here, we evaluate the safety of empagliflozin and provide an expert opinion as to its current and future role in the treatment of patients with T2DM. A search of the English language literature was performed using PubMed search terms: "empagliflozin", "sodium glucose cotransporter 2 inhibitors", and "drug safety". Articles and bibliographies relevant to the subject were reviewed and additional references known to the authors were included.Expert Opinion: The evidence for empagliflozin is robust with regard to glycemic efficacy and safety. Low risk of hypoglycemia, absence of weight gain, and demonstrated cardiovascular risk reduction support its consideration as a first line medication in addition to metformin for patients with T2DM and CVD. Ongoing trials will continue to address the safety and efficacy of empagliflozin and expand our clinical knowledge of this medication.

KW - drug safety

KW - empagliflozin

KW - sodium glucose co-transporter 2 inhibitor

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84959546060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959546060&partnerID=8YFLogxK

U2 - 10.1517/14740338.2016.1135900

DO - 10.1517/14740338.2016.1135900

M3 - Article

C2 - 26695551

AN - SCOPUS:84959546060

VL - 15

SP - 393

EP - 402

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 3

ER -